Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prometheus Biosciences, Inc. - Common Stock (NQ: RXDX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 15, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Prometheus Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Benzinga's Top Ratings Upgrades, Downgrades For April 17, 2023
Via Benzinga
US Stocks Mostly Flat; NY Empire State Manufacturing Index Surges In April
U.S. stocks traded mostly flat this morning, following the release of economic data. Following the market opening Monday, the Dow traded up 0.04% to 33,901.46 while the NASDAQ fell 0.09% to 12,112.19.... 
Via Benzinga
Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom
Merck is branching into immune-mediated diseases with this takeover. 
Via Investor's Business Daily
Analyst Expectations for Prometheus Biosciences's Future
Via Benzinga
Analyst Expectations for Prometheus Biosciences's Future
Via Benzinga
Looking Into Prometheus Biosciences's Return On Capital Employed
Via Benzinga
Where Prometheus Biosciences Stands With Analysts
Via Benzinga
PRST Stock Alert: What to Know About Red-Hot Presto Automation Today
Presto Automation (PRST) stock is seeing massive gains with heavy trading on Monday despite a lack of news from the AI company. 
Via InvestorPlace
Why Is NIO Stock Up Today?
Nio (NIO) stock is climbing higher on Monday after the EV company announced the launch of its new power charging stations. 
Via InvestorPlace
RXDX Stock Alert: The $10.8 Billion Reason Prometheus Biosciences Is Surging Today
RXDX stock is soaring today as Merck is officially acquiring Prometheus Biosciences. Here's what investors should know today. 
Via InvestorPlace
Why Is SAI.TECH Global (SAI) Stock Down 32% Today?
SAI.TECH Global (SAI) stock is down on Monday despite a lack of news concerning the Bitcoin (BTC-USD) mining and clean energy company. 
Via InvestorPlace
Why Is Marpai (MRAI) Stock Down 40% Today?
Marpai (MRAI) stock is taking a beating on Monday after the company announced a proposed public offering for its shares. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
XPeng Is Charging Higher, but This Biotech Stock Is Monday's Biggest Winner
Markets are watching corporate earnings very carefully. 
Via The Motley Fool
Why Is Prometheus Biosciences (RXDX) Stock Up 70% Today?
Prometheus Biosciences (RXDX) stock is on the rise Monday after the company revealed a $10.8 billion acquisition deal with Merck (MRK). 
Via InvestorPlace
Why Marpai Shares Are Trading Lower By 26%; Here Are 20 Stocks Moving Premarket
Gainers CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) jumped 153% to $5.96 in pre-market trading after jumping 243% on Friday. 
Via Benzinga
Merck Acquires Prometheus Biosciences For $10.8B, Strengthening Its Immunology Pipeline
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting the week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday morning! 
Via InvestorPlace
Nasdaq, S&P 500 Futures Muted; Analyst Says Don't Expect Good News This Earnings Season
Early indications suggest that stocks could start the week on a tentative note, which was characteristic of trading during most of last week. Traders may show restraint as they look ahead to... 
Via Benzinga
Prometheus Biosciences, XPeng And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 70.1% to $193.93... 
Via Benzinga
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
How Is The Market Feeling About Prometheus Biosciences?
Prometheus Biosciences's (NASDAQ:RXDX) short percent of float has fallen 35.76% since its last report. The company recently reported that it has 3.43 million shares sold short, which is 8.3% of all... 
Via Benzinga
Bulls In A Bear Market: These 10 Stocks Clocked Gains In Excess Of 100% In 2022
2022 would go down as one of the worst years for the financial markets. The sell-off has been all-pervasive, with stocks, bonds and cryptos all selling off indiscriminately. Even as high-fliers like... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Universal Health Services, Madrigal Pharmaceuticals And These Overbought Majors In The Healthcare Sector
The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Why Prometheus Biosciences Stock Is Falling
Prometheus Biosciences Inc (NASDAQ: RXDX) shares are trading lower by 6.01% to $110.16 going into the close of Friday's session after the company priced a public upsized $500 million offering. 
Via Benzinga
Is Prometheus Biosciences a Good Stock to Buy Right Now?
This biotech stock just jumped over 180% in a single day, and investors want to know if there could be more big gains ahead. 
Via The Motley Fool
Why Prometheus Biosciences Stock Is Rocketing Higher Today
Prometheus Biosciences Inc (NASDAQ: RXDX) shares are trading higher Thursday after multiple analyst firms raised price targets on the stock following positive results from the company's PRA023 in both 
Via Benzinga
Analyzing Prometheus Biosciences's Short Interest
Prometheus Biosciences's (NASDAQ:RXDX) short percent of float has risen 5.39% since its last report. The company recently reported that it has 4.89 million shares sold short, which is 13.3% of all... 
Via Benzinga
Why Shares of Prometheus Biosciences Are Soaring This Week
The clinical-stage biotech that specializes in IBD therapies announced positive news regarding two trials for its lead therapy. 
Via The Motley Fool
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.